Frankfurt - Delayed Quote EUR

Vaxcyte, Inc. (5VA.F)

Compare
69.50
-1.00
(-1.42%)
At close: March 3 at 8:08:39 AM GMT+1

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Grant E. Pickering M.B.A. Co-Founder, CEO & Director 1.09M 1.16M 1968
Mr. Andrew L. Guggenhime M.B.A. President & CFO 791.07k 1.83M 1968
Mr. James Wassil M.B.A., M.S. Executive VP & COO 502.17k 909.42k 1970
Mr. Mikhail Eydelman J.D. Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary 659.81k 896.91k 1982
Dr. Jeff Fairman Ph.D. Co-Founder & VP of Research -- -- 1965
Ms. Janet Graesser Senior Vice President of Corporate Communications & Investor Relations -- -- --
Ms. Whitney Jones Chief People Officer -- -- --
Mr. Paul W. Sauer M.B.A. Senior Vice President of Process Development & Manufacturing 586.89k -- 1962
Mr. Harp Dhaliwal M.B.A. Chief Technical Operations Officer 141.18k -- 1974
Sam Iki Senior Vice President of Project Management -- -- --

Vaxcyte, Inc.

825 Industrial Road
Suite 300
San Carlos, CA 94070
United States
(650) 837-0111 https://vaxcyte.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
414

Description

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Corporate Governance

Vaxcyte, Inc.’s ISS Governance QualityScore as of March 1, 2025 is 7. The pillar scores are Audit: 5; Board: 5; Shareholder Rights: 8; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 6, 2025 at 8:00 PM UTC - May 12, 2025 at 8:00 PM UTC

Vaxcyte, Inc. Earnings Date

Recent Events

Related Tickers